New treatment approaches in CLL MEDSTAT_JS MEDSTAT_CSS

New treatment approaches in CLL

Over the last decade, the introduction of new treatment classes has caused a shift from chemoimmunotherapy as the standard of care for chronic lymphocytic leukemia (CLL). In this video roundtable series, Dr. Nilanjan Ghosh is joined by Dr. Matthew Davids and Dr. Anthony Mato for a discussion about the role of BTK inhibitors and BCL2 inhibitors within the CLL treatment landscape, approaches for therapy sequencing, and the importance of MRD monitoring.

Video 1: BTK inhibitors

Several highly-effective BTK inhibitors are FDA-approved for the treatment of CLL, with more new agents potentially on the way. In this video, the panel discusses considerations for choosing which BTK inhibitors to use in different patient scenarios as well as the promising LOXO-305 data.

Up Next

Video 1: BTK inhibitors
Video 2: BCL2 inhibitors
Video 3: Sequencing therapies
Video 4: MRD monitoring

MEDSTAT_LATEST_NEWS_WIDGET

About the Panel

Dr. Ghosh Photo

Nilanjan Ghosh, MD, PhD

  • Chief
  • Department of Hematologic Malignancies and Blood Disorders, Lymphoma Division
  • Levine Cancer Institute, Atrium Health
  • Charlotte, NC
Dr. Davids Photo

Matthew S. Davids, MD, MMSc

  • Associate Professor
  • Department of Medicine
  • Harvard Medical School
  • Director, Clinical Research, Department of Medicine, Division of Lymphoma
  • Dana-Farber Cancer Institute
  • Boston, MA
Dr. Mato Photo

Anthony Mato, MD, MSCE

  • Director
  • Chronic Lymphocytic Leukemia Program
  • Memorial Sloan Kettering Cancer Center
  • New York, NY
Disclosures

Nilanjan Ghosh, MD, PhD, has disclosed the following relevant financial relationships:
Serve(d) as a speaker or a member of a speakers bureau for: Kite Pharma; AstraZeneca; AbbVie; Janssen; Bristol-Myers Squibb; Epizyme
Received research grant from: Genentech/Roche; Bristol-Myers Squibb; TG Therapeutics; Pharmacyclics; Kite Pharma
Received income in an amount equal to or greater than $250 from: Kite Pharma; AstraZeneca; AbbVie; Janssen; Bristol-Myers Squibb; Incyte; Epizyme; Karyopharma; Genmab; Adaptive Biotech; TG Therapeutics

Matthew S. Davids, MD, MMSc, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: AbbVie; Adaptive Biotechnologies; AstraZeneca; BeiGene; Eli Lilly and Company; Genentech; Janssen; Merck; TG Therapeutics; Verastem
Received research grant from: AbbVie; Ascentage Pharma; AstraZeneca; Genentech; MEI Pharma; Novartis; Pharmacyclics; Surface Oncology; TG Therapeutics; Verastem
Received honoraria from: Research to Practice

Anthony Mato, MD, MSCE, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: TG Therapeutics; AbbVie; Pharmacyclics; Johnson and Johnson; AstraZeneca; Genentech; Adaptive; Loxo Oncology; Sunesis; GenMAB; Nurix; Determine; Octopharma
Received research grant from: TG Therapeutics; AbbVie; Pharmacyclics; Johnson and Johnson; AstraZeneca; Genentech; Adaptive; Loxo Oncology